.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,772,497

« Back to Dashboard

Claims for Patent: 8,772,497

Title:Method for producing 1, 2-dihydropyridine-2-one compound
Abstract: The present inventions provide a method for commercially producing a 1,2-dihydropyridine-2-one compound represented by the following formula (III-a) ##STR00001## wherein the ring A represents an optionally substituted 2-pyridyl group, the ring B represents an optionally substituted phenyl group, and the ring C represents an optionally substituted phenyl group. Further, the invention provides crystals of 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one and production processes therefore.
Inventor(s): Arimoto; Itaru (Tokyo, JP), Nagato; Satoshi (Tokyo, JP), Sugaya; Yukiko (Tsukuba, JP), Urawa; Yoshio (Kamisu, JP), Ito; Koichi (Tsukuba, JP), Naka; Hiroyuki (Kamisu, JP), Omae; Takao (Tsukuba, JP), Kayano; Akio (Kamisu, JP), Nishiura; Katsutoshi (Kamisu, JP)
Assignee: Eisai R&D Management Co., Ltd. (Tokyo, JP)
Application Number:12/870,507
Patent Claims: 1. A crystal of 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one hydrate having a diffraction peak at a diffraction angle (2.theta..+-.0.2.degree.) of 8.7.degree. in a powder X-ray diffraction.

2. A crystal of 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one hydrate having a diffraction peak at a diffraction angle (2.theta..+-.0.2.degree.) of 12.5.degree. in a powder X-ray diffraction.

3. A crystal of 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one hydrate having diffraction peaks at diffraction angles (2.theta..+-.0.2.degree.) of 8.7.degree. and 12.5.degree. in a powder X-ray diffraction.

4. A crystal of 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one hydrate having an absorption peak at a wavenumber of 1588.+-.1 cm.sup.-1 in an infrared absorption spectrum (KBr method).

5. A crystal of 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one hydrate having absorption peaks at wavenumbers of 1588.+-.1 cm.sup.-1 and 751.+-.1 cm.sup.-1 in an infrared absorption spectrum (KBr method).

6. A crystal of 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one hydrate having peaks at chemical shifts of around 146.7 ppm and around 123.3 ppm in a .sup.13C Solid State Nuclear Magnetic Resonance spectrum.

7. A process for producing a crystal of 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one hydrate, the process comprising the step of crystallizing 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one with an aid of one or two crystallization solvents selected from the group consisting of an alcoholic solvent, an alkylketone solvent, and water, wherein the 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one hydrate has (a) a diffraction peak at a diffraction angle (2.theta..+-.0.2.degree.) of 8.7.degree. in a powder X-ray diffraction, (b) a diffraction peak at a diffraction angle (2.theta..+-.0.2.degree.) of 12.5.degree. in a powder X-ray diffraction, (c) diffraction peaks at diffraction angles (2.theta..+-.0.2.degree.) of 8.7.degree. and 12.5.degree. in a powder X-ray diffraction, (d) an absorption peak at a wavenumber of 1588.+-.1 cm.sup.-1 in an infrared absorption spectrum (KBr method), (e) absorption peaks at wavenumbers of 1588.+-.1 cm.sup.-1 and 751.+-.1 cm.sup.-1 in an infrared absorption spectrum (KBr method) or, (f) peaks at chemical shifts of around 146.7 ppm and around 123.3 ppm in a .sup.13C Solid State Nuclear Magnetic Resonance spectrum, (g) diffraction peaks at diffraction angles (20.+-.0.2.degree.) of 7.78.degree., 8.70.degree. and 24.19.degree. in a powder X-ray diffraction, (h) diffraction peaks at diffraction angles (2.theta..+-.0.2.degree.) of 7.78.degree., 8.70.degree., 9.52.degree., 12.45.degree. and 24.19.degree. in a powder X-ray diffraction, (i) diffraction peaks at diffraction angles (2.theta..+-.0.2.degree.) of 7.78.degree., 8.70.degree., 9.52.degree., 12.45.degree., 15.24.degree., 17.54.degree., 23.26.degree., 24.19.degree., 25.44.degree. and 26.43.degree. in a powder X-ray diffraction, (j) diffraction peaks at diffraction angles (2.theta..+-.0.2.degree. of 7.78.degree., 8.70.degree., 9.52.degree., 12.45.degree., 14.59.degree., 15.24.degree., 15.60.degree., 16.18.degree., 17.54.degree., 19.98.degree., 21.04.degree., 21.42.degree., 23.26.degree., 24.19.degree., 25.44.degree., 25.82.degree., 26.43.degree., 27.31.degree., 27.86.degree. and 28.87.degree. in a powder X-ray diffraction, (k) absorption peaks at wavenumbers of 1661.37.+-.1 cm.sup.-1, 1482.03.+-.1 cm.sup.-1, 1282.43.+-.1 cm.sup.-1, 899.63.+-.1 cm.sup.-1 and 784.89.+-.1 cm.sup.-1 in an infrared absorption spectrum (KBr method), (l) absorption peaks at wavenumbers of 3406.64.+-.1 cm.sup.-1, 2217.74.+-.1 cm.sup.-1, 1661.37.+-.1 cm.sup.-1, 1619.91.+-.1 cm.sup.-1, 1588.09.+-.1 cm.sup.-1, 1566.88.+-.1 cm.sup.-1, 1550.49.+-.1 cm.sup.-1, 1482.03.+-.1 cm.sup.-1, 1434.78.+-.1 cm.sup.-1, 1369.21.+-.1 cm.sup.-1, 1318.11.+-.1 cm.sup.-1, 1282.43.+-.1 cm.sup.-1, 1249.65.+-.1 cm.sup.-1, 1157.08.+-.1 cm.sup.-1, 1099.23.+-.1 cm.sup.-1, 899.63.+-.1 cm.sup.-1, 879.38.+-.1 cm.sup.-1, 784.89.+-.1 cm.sup.-1, 751.14.+-.1 cm.sup.-1, 730.89.+-.1 cm.sup.-1, 697.14.+-.1 cm.sup.-1, 606.50.+-.1 cm.sup.-1, 557.33.+-.1 cm.sup.-1 and 505.26.+-.1 cm.sup.-1 in an infrared absorption spectrum (KBr method), (m) peaks at chemical shifts of around 146.7 ppm, around 139.4 ppm, around 132.7 ppm, around 123.3 ppm, around 120.8 ppm and around 118.4 ppm in a .sup.13C Solid State Nuclear Magnetic Resonance spectrum, (n) peaks at chemical shifts of around 159.8 ppm, around 150.8 ppm, around 146.7 ppm, around 139.4 ppm, around 136.6 ppm, around 134.9 ppm, around 132.7 ppm, around 129.0 ppm, around 127.8 ppm, around 126.5 ppm, around 125.8 ppm, around 123.3 ppm, around 120.8 ppm, around 118.4 ppm, around 114.6 ppm and around 108.8 ppm in a .sup.13C Solid State Nuclear Magnetic Resonance spectrum, (o) a powder X-ray diffraction pattern shown in FIG. 4, (p) an infrared spectrum (KBr method) shown in FIG. 1 or (q) a .sup.13C Solid State NMR spectrum shown in FIG. 8.

8. The process according to claim 7, wherein the crystallization solvent is a mixed solvent of acetone and water.

9. The process according to claim 7, wherein the crystallization solvent is a mixed solvent of acetone and water with a volume ratio of 37:3 to 24:16.

10. The process according to claim 7, wherein the crystallization is carried out at a temperature of 60 to -30.degree. C.

11. The process according to claim 7 comprising the steps of heating a solution of 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one dissolved in the crystallization solvent at a temperature of 50.degree. C. or more and thereafter cooling the solution to a temperature of 10 to -20.degree. C. at a cooling rate of 40 to 5.degree. C. per hour.

12. The process according to claim 7, wherein the crystallization solvent is used in a volume ratio of 10- to 50-fold (v/w) based on the weight of 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one.

13. The process according to claim 7, wherein seed crystals are added at 60.degree. C. or less.

14. The process according to claim 7, wherein the crystals are dried under reduced pressure after the crystallization.

15. The process according to claim 7, wherein the crystals are allowed to stand in the atmosphere after the crystallization and the drying under reduced pressure.

16. A crystal of 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one hydrate having diffraction peaks at diffraction angles (2.theta..+-.0.2.degree.) of 7.78.degree., 8.70.degree. and 24.19.degree. in a powder X-ray diffraction.

17. A crystal of 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one hydrate having diffraction peaks at diffraction angles (2.theta..+-.0.2.degree.) of 7.78.degree., 8.70.degree., 9.52.degree., 12.45.degree. and 24.19.degree. in a powder X-ray diffraction.

18. A crystal of 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one hydrate having diffraction peaks at diffraction angles (2.theta..+-.0.2.degree.) of 7.78.degree., 8.70.degree., 9.52.degree., 12.45.degree., 15.24.degree., 17.54.degree., 23.26.degree., 24.19.degree., 25.44.degree. and 26.43.degree. in a powder X-ray diffraction.

19. A crystal of 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one hydrate having diffraction peaks at diffraction angles (2.theta..+-.0.2.degree.) of 7.78.degree., 8.70.degree., 9.52.degree., 12.45.degree., 14.59.degree., 15.24.degree., 15.60.degree., 16.18.degree., 17.54.degree., 19.98.degree., 21.04.degree., 21.42.degree., 23.26.degree., 24.19.degree., 25.44.degree., 25.82.degree., 26.43.degree., 27.31.degree., 27.86.degree. and 28.87.degree. in a powder X-ray diffraction.

20. A crystal of 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one hydrate having absorption peaks at wavenumbers of 1661.37.+-.1 cm.sup.-1, 1482.03.+-.1 cm.sup.-1, 1282.43.+-.1 cm.sup.-1, 899.63.+-.1 cm.sup.-1 and 784.89.+-.1 cm.sup.-1 in an infrared absorption spectrum (KBr method).

21. A crystal of 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one hydrate having absorption peaks at wavenumbers of 3406.64.+-.1 cm.sup.-1, 2217.74.+-.1 cm.sup.-1, 1661.37.+-.1 cm.sup.-1, 1619.91.+-.1 cm.sup.-1, 1588.09.+-.1 cm.sup.-1, 1566.88.+-.1 cm.sup.-1, 1550.49.+-.1 cm.sup.-1, 1482.03.+-.1 cm.sup.-1, 1434.78.+-.1 cm.sup.-1, 1369.21.+-.1 cm.sup.-1, 1318.11.+-.1 cm.sup.-1, 1282.43.+-.1 cm.sup.-1, 1249.65.+-.1 cm.sup.-1, 1157.08.+-.1 cm.sup.-1, 1099.23.+-.1 cm.sup.-1, 899.63.+-.1 cm.sup.-1, 879.38.+-.1 cm.sup.-1, 784.89.+-.1 cm.sup.-1, 751.14.+-.1 cm.sup.-1, 730.89.+-.1 cm.sup.-1, 697.14.+-.1 cm.sup.-1, 606.50.+-.1 cm.sup.-1, 557.33.+-.1 cm.sup.-1 and 505.26.+-.1 cm.sup.-1 in an infrared absorption spectrum (KBr method).

22. A crystal of 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one hydrate having peaks at chemical shifts of around 146.7 ppm, around 139.4 ppm, around 132.7 ppm, around 123.3 ppm, around 120.8 ppm and around 118.4 ppm in a .sup.13C Solid State Nuclear Magnetic Resonance spectrum.

23. A crystal of 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one hydrate having peaks at chemical shifts of around 159.8 ppm, around 150.8 ppm, around 146.7 ppm, around 139.4 ppm, around 136.6 ppm, around 134.9 ppm, around 132.7 ppm, around 129.0 ppm, around 127.8 ppm, around 126.5 ppm, around 125.8 ppm, around 123.3 ppm, around 120.8 ppm, around 118.4 ppm, around 114.6 ppm and around 108.8 ppm in a .sup.13C Solid State Nuclear Magnetic Resonance spectrum.

24. A crystal of 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one hydrate having a powder X-ray diffraction pattern shown in FIG. 4.

25. A crystal of 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one hydrate having an infrared spectrum (KBr method) shown in FIG. 1.

26. A crystal of 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one hydrate having a .sup.13C Solid State NMR spectrum shown in FIG. 8.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc